Standard Dosing Schedule for Prolia
Prolia (denosumab) is given as a 60 mg subcutaneous injection every 6 months for osteoporosis treatment in postmenopausal women, men at high risk for fracture, or patients with glucocorticoid-induced osteoporosis.[1]
How Is Prolia Administered?
A healthcare provider injects Prolia into the upper arm, upper thigh, or abdomen. Patients do not self-administer it. Each dose comes pre-filled in a single-use syringe.[1]
Why Every 6 Months?
Prolia targets RANKL to inhibit osteoclast activity, providing bone protection for up to 6 months per dose. Clinical trials showed sustained fracture risk reduction with this interval, balancing efficacy and convenience over daily or monthly bisphosphonates.[1][2]
Dosage for Other Conditions
For bone loss from cancer treatments like hormone therapy for breast or prostate cancer, the schedule remains 60 mg every 6 months. No adjustments for renal impairment above creatinine clearance of 30 mL/min.[1]
What Happens If You Miss a Dose?
Administer the missed dose as soon as possible, then resume the 6-month schedule. If the delay exceeds 1 month from the due date, consult a doctor to assess timing and monitor bone health.[1]
Prolia vs. Other Osteoporosis Drugs
| Drug | Frequency | Type |
|------|-----------|------|
| Prolia | Every 6 months (injection) | Monoclonal antibody |
| Fosamax (alendronate) | Weekly (oral) | Bisphosphonate |
| Reclast (zoledronic acid) | Yearly (IV infusion) | Bisphosphonate |
| Forteo (teriparatide) | Daily (self-injection) | Anabolic agent |
Prolia offers fewer administrations than dailies but requires clinic visits unlike orals.[1][3]
Common Patient Concerns on Scheduling
Patients often ask about travel or adherence—pre-plan injections around routines. Long-term use needs calcium/vitamin D supplements and dental checks due to osteonecrosis risk. Discontinuation requires transition to another agent to avoid rebound fractures.[1][2]
[1]: Prolia Prescribing Information
[2]: FDA Label for Denosumab
[3]: DrugPatentWatch.com - Prolia Patents and Exclusivity